Ardelyx Secures Key Patent for Tenapanor, Extending Market Exclusivity for Kidney Disease Drugs to 2042
Biopharmaceutical firm Ardelyx has been granted a crucial U.S. patent covering the oral formulation of its drug tenapanor, solidifying protection for its commercial products Ibsrela and Xphozah until late 2042 and bolstering its competitive position in the chronic kidney disease treatment landscape.